4//SEC Filing
EMSTER KURT VON 4
Accession 0001062993-23-018622
CIK 0001042074other
Filed
Sep 28, 8:00 PM ET
Accepted
Sep 29, 5:54 PM ET
Size
20.1 KB
Accession
0001062993-23-018622
Insider Transaction Report
Form 4
EMSTER KURT VON
Director
Transactions
- Sale
Common Stock
2023-09-29$15.68/sh−15,921$249,675→ 90,000 total - Exercise/Conversion
Employee Stock Option (right to buy)
2023-09-29−5,249→ 0 totalExercise: $5.00Exp: 2024-01-05→ Common Stock (5,249 underlying) - Exercise/Conversion
Common Stock
2023-09-29$5.00/sh+15,921$79,605→ 105,921 total - Exercise/Conversion
Employee Stock Option (right to buy)
2023-09-29−6,357→ 0 totalExercise: $5.00Exp: 2023-10-30→ Common Stock (6,357 underlying) - Exercise/Conversion
Stock Appreciation Right
2023-09-29−3,372→ 0 totalExercise: $5.00Exp: 2023-12-22→ Common Stock (3,372 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2023-09-29−943→ 0 totalExercise: $5.00Exp: 2023-12-22→ Common Stock (943 underlying)
Holdings
- 18,406(indirect: By Trust)
Common Stock
Footnotes (7)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on June 30, 2023.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.54 to $15.89, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]This corrects a typographical error made in the reporting person's previous Form 4 filings. In filings between October 2, 2017 and March 17, 2018 (inclusive) the reporting person reported 17,236 shares held indirectly rather than the 17,326 shares that the reporting person actually held indirectly (and had reported previously). After adding 1,080 shares on June 5, 2018 the reporting person incorrectly reported in a filing on June 7, 2018 and in filings thereafter owning 18,316 shares indirectly rather than the 18,406 shares that the reporting person actually held indirectly.
- [F4]The option vested as to 1/3 of the underlying shares on October 31, 2013 and the remaining 2/3 of the underlying shares vested ratably on a monthly basis over the 48 months thereafter.
- [F5]The option vested as to 1/4 of the underlying shares on April 2, 2010 and the remaining 3/4 of the underlying shares vested ratably on a monthly basis over the 36 months thereafter.
- [F6]The incentive award (the "Award") was granted under the CymaBay 2013 Equity Incentive Plan and could be settled in cash or shares of CymaBay common stock, at the sole discretion of CymaBay. The shares subject to the Award vested in 48 equal monthly installments from the grant date.
- [F7]The option vested as to 1/3 of the underlying shares on January 6, 2014 and the remaining 2/3 of the underlying shares vested ratably on a monthly basis over the 48 months thereafter.
Issuer
CymaBay Therapeutics, Inc.
CIK 0001042074
Entity typeother
Related Parties
1- filerCIK 0001252524
Filing Metadata
- Form type
- 4
- Filed
- Sep 28, 8:00 PM ET
- Accepted
- Sep 29, 5:54 PM ET
- Size
- 20.1 KB